APA (7th ed.) Citation

Y, F., Y, D., Z, T., S, C., J, L., R, L., . . . W, Z. (2023). Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer. Frontiers in endocrinology, 14, 1148898. https://doi.org/10.3389/fendo.2023.1148898

Chicago Style (17th ed.) Citation

Y, Feng, et al. "Prognostic Implication of Heterogeneity and Trajectory Progression Induced by Enzalutamide in Prostate Cancer." Frontiers in Endocrinology 14 (2023): 1148898. https://doi.org/10.3389/fendo.2023.1148898.

MLA (9th ed.) Citation

Y, Feng, et al. "Prognostic Implication of Heterogeneity and Trajectory Progression Induced by Enzalutamide in Prostate Cancer." Frontiers in Endocrinology, vol. 14, 2023, p. 1148898, https://doi.org/10.3389/fendo.2023.1148898.